1. Home
  2. OSUR vs CRDF Comparison

OSUR vs CRDF Comparison

Compare OSUR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OraSure Technologies Inc.

OSUR

OraSure Technologies Inc.

HOLD

Current Price

$2.40

Market Cap

177.2M

Sector

Health Care

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$2.55

Market Cap

142.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSUR
CRDF
Founded
2000
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.2M
142.1M
IPO Year
1986
N/A

Fundamental Metrics

Financial Performance
Metric
OSUR
CRDF
Price
$2.40
$2.55
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$3.00
$10.63
AVG Volume (30 Days)
742.3K
914.5K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$125,703,000.00
$501,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$1.90
52 Week High
$4.22
$5.00

Technical Indicators

Market Signals
Indicator
OSUR
CRDF
Relative Strength Index (RSI) 43.86 65.93
Support Level $2.41 $2.32
Resistance Level $2.53 $2.59
Average True Range (ATR) 0.11 0.13
MACD 0.01 0.03
Stochastic Oscillator 15.52 94.69

Price Performance

Historical Comparison
OSUR
CRDF

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: